AU2003250344A1 - Determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein - Google Patents
Determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein Download PDFInfo
- Publication number
- AU2003250344A1 AU2003250344A1 AU2003250344A AU2003250344A AU2003250344A1 AU 2003250344 A1 AU2003250344 A1 AU 2003250344A1 AU 2003250344 A AU2003250344 A AU 2003250344A AU 2003250344 A AU2003250344 A AU 2003250344A AU 2003250344 A1 AU2003250344 A1 AU 2003250344A1
- Authority
- AU
- Australia
- Prior art keywords
- group
- component
- components
- donor
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000003993 interaction Effects 0.000 title claims description 13
- 108010074051 C-Reactive Protein Proteins 0.000 title description 74
- 102100032752 C-reactive protein Human genes 0.000 title description 74
- 239000000470 constituent Substances 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 117
- 238000000034 method Methods 0.000 claims description 73
- 230000005670 electromagnetic radiation Effects 0.000 claims description 21
- 238000003556 assay Methods 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 16
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 13
- 230000005284 excitation Effects 0.000 claims description 12
- 210000002966 serum Anatomy 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 7
- 230000003213 activating effect Effects 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000013543 active substance Substances 0.000 claims description 3
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 208000010496 Heart Arrest Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 238000002405 diagnostic procedure Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 19
- 239000011324 bead Substances 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000024203 complement activation Effects 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000013537 high throughput screening Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 108010090804 Streptavidin Proteins 0.000 description 3
- 238000007413 biotinylation Methods 0.000 description 3
- 230000006287 biotinylation Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 238000003016 alphascreen Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229950004354 phosphorylcholine Drugs 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000003284 AlphaScreen IgG detection kit Methods 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 150000000918 Europium Chemical class 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 239000012901 Milli-Q water Substances 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 description 1
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- RPENMORRBUTCPR-UHFFFAOYSA-M sodium;1-hydroxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].ON1C(=O)CC(S([O-])(=O)=O)C1=O RPENMORRBUTCPR-UHFFFAOYSA-M 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Description
IN THE MATTER OF an Australian Application corresponding to PCT Application PCT/EPO3/06038 RWS Group Ltd, of Europa House, Marsham Way, Gerrards Cross, Buckinghamshire, England, hereby solemnly and sincerely declares that, to the best of its knowledge and belief, the following document, prepared by one of its translators competent in the art and conversant with the English and German languages, is a true and correct translation of the PCT Application filed under No. PCT/EPO3/06038. Date: 16 August 2004 S. ANTHONY Director For and on behalf of RWS Group Ltd WO 03/107000 PCT/EPO3/06038 Description HTS-capable method and testing system for determining the interaction between a C 5 reactive protein and constituents that bind to a C-reactive protein The present invention relates to an HTS-capable method and assay system for determining the interaction between C-reactive protein (CRP) and Clq and components binding to CRP and Clq, respectively, to determining the concentration ) of a solution containing CRP and Clq, respectively, and to determining substances which influence the interaction of CRP and Clq, respectively, and components binding thereto. The C-reactive protein (CRP) is an acute-phase plasma protein whose serum 5 concentration increases rapidly and greatly after an infection or tissue injury (Volanakis (2001), Molecular Immunology 38, 189-197). CRP binds to phosphocholine (PCh) in the presence of Ca 2+ ions. The latter is very common in polysaccharides of pathogenic organisms and in cell membranes of damaged and necrotic cells. CRP bound to PCh can activate the classical complement cascade by D binding to the protein Clq. The complement is part of the immune system and primarily involved in the antibody mediated immune defenses. The three physiological functions of the complement are the defense against bacterial infections, the connection of congenital and acquired 5 immunity and the removal of immunocomplexes and apoptotic cells. A distinction is made between the classical, the alternative and the mannose-lectin complement cascades (Walport (2001), N Engl J Med 344, 1058-1066). The classical complement cascade leads to the lysis of bacterial cells and starts with Clq associating with an antibody binding to the cell surface or with PCh-bound CRP.
)
2 C-reactive protein is used as a marker and, in addition, as a predictor for coronary heart disease, the most common cause of mortality in industrialized countries (Rifai and Ridker (2001), Clinical Chemistry 47, 403-411). 5 Owing to new studies (Jialal et al (2001), Circulation 103, 1933-1935), it is assumed that lowering the CRP level or blocking the CRP-mediated effector functions, for example complement activation due to binding to Clq, may be useful for the prevention and treatment of coronary heart disease. ) It is therefore desirable firstly to provide a method which allows determining the concentration of CRP and/or Clq in blood plasma in a simple manner and, secondly, allows identification of substances which act on the interaction of CRP and/or Clq with other components, in particular on the interaction between CRP and Clq, in a modulating, i.e. activating or inhibiting, way. Methods for determining the binding of CRP to Clq have been described, for example, by Jiang et al. (1991), J. Immunol. 146, 2324-2330 and Agrawal et al. (2001), J. Immunol. 166, 3998-4004. Both publications make use of an ELISA method. Both are very time- and material-consuming, multistage inhomogeneous ) methods. Thus, in order to carry out the method, one of the reactants always needs initially to be immobilized to a solid phase. Moreover, numerous washing steps are required. Lebdue et al. (1998), Ann Clin Biochem 35, 745-753 describe a method for 5 immunonephelometric detection of CRP. To this end, the sample is incubated with anti-CRP antibodies loaded with polystyrene particles. Said method has a crucial disadvantage in that a nephelometer is required and a relatively large quantity of sample must be used in order to carry it out. ) It was therefore the object of the present invention to provide a method which allows the concentration of CRP or Clq in blood plasma to be determined in a simple manner and which furthermore allows the identification of substances which act on 3 the interaction of CRP or Clq with other components, in particular on the interaction between Clq and CRP, in a modulating, activating or inhibiting manner, and said method is distinguished advantageously compared to the prior art by being more sensitive, cost-effective, material-saving, simpler and/or more rapidly carried out than the previously described methods. The object is achieved by a method for determining a binding event of two components binding directly or via one or more components to CRP or Clq, which comprises the following steps: ) (a) initially introducing a CRP- or Clq-containing solution, (b) adding at least one donor component or a group of components containing at least one donor component to said CRP- or Clq-containing solution, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said donor component being capable of binding directly or via one or more components from said group of components to CRP or Clq, (c) adding at least one acceptor component or a group of components containing at least one acceptor component to said CRP- or Clq-containing solution, said acceptor component being a component which comprises at least one compound or group of ) compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to CRP or Clq, (d) exciting the at least one compound or group of compounds according to (b) p (donor group) by means of a light source, (e) detecting the electromagnetic radiation emitted by the at least one compound or group of compounds according to (c) (acceptor group) in order to detect said binding event. ) The emitted electromagnetic radiation according to (c) is here preferably fluorescence radiation. The light source according to (d) may be, for example, a laser 4 or a lamp, for example a helium or halogen lamp. The electromagnetic radiation according to (e) may be detected, for example, with the aid of a photomultiplier. The components to be used according to the invention preferably are or comprise 5 polypeptides. In a particularly preferred embodiment of the invention, at least one of the components is an antibody which may be a monoclonal or polyclonal antibody. If a group of components is used, said components are preferably capable of binding to CRP or Clq or to one another in spatial succession. Said binding takes place in 0 the form of a binding cascade, an example of which is the successive binding of antibodies (primary antibody, secondary antibody, etc.). The components binding directly to CRP or Clq according to (b) and (c) are here preferably components which bind in each case to a particular binding region or to a particular epitope of the CRP or Clq, said CRP- or Clq-binding component according to (b) binding to a 5 different binding site than the CRP- or Clq-binding component according to (c). In another preferred embodiment of the method of the invention, one of the components binding directly to CRP or Clq is a naturally occurring binding partner of the CRP or Cl1q, which, in case of the CRP is particularly preferably Cl1q and vice D) versa. If the donor or acceptor component is bound directly to CRP or Clq, then, in this case, either the donor or the acceptor component is accordingly either Clq or CRP comprising a donor or acceptor group. When using a group of components capable of forming a binding cascade, Cl1q or CRP is accordingly the first component binding to CRP or Clq via which it is possible to bind either the donor or the acceptor 5 component to CRP or Cl1q. The remaining components of the group of components are particularly preferably antibody molecules. Thus, for example, when initially introducing a CRP-containing solution, then, in this embodiment, preferably either the donor or the acceptor component itself comprises ) Clq or the donor or acceptor component is bound via Clq to CRP. In this case, the donor or acceptor component may comprise an anti-Clq antibody or a secondary antibody capable of binding to said anti-Cl q antibody. Accordingly, the in each case 5 other component (acceptor or donor component) then comprises an anti-CRP antibody or an antibody capable of binding to the anti-CRP antibody or a tertiary antibody directed against the latter. In a preferred embodiment, the at least one compound or group of compounds according to (b) (donor group) and/or according to (c) (acceptor group) are localized on particles, with the average diameter of said particles preferably being between 150 and 250 nm, particularly preferably at approximately 200 nm. Accordingly, the donor or acceptor components then comprise said particles which, in this case, may ) be made of a polymeric material. The method of the invention is an HTS (high throughput screening)-capable method which may be carried out homogeneously in the form of a one-step method. In a preferred embodiment, the method of the invention is carried out according to the "mix and measure" principle, resulting in considerable time-savings and higher accuracy of the measured data. The method of the invention allows the binding of CRP to Clq to be measured, and ) thus the identification of substances influencing said binding, and the concentration of CRP or Clq in complex media to be measured in less than 10 percent of the time which was required when using previously described inhomogeneous methods. A particular characteristic feature of the novel method is the possibility of monitoring i binding between the two proteins in solution, since none of the reactants need be immobilized on a solid phase. Moreover, it is possible to measure the proteins obtained from biological sources directly, without the need for modifying CRP or Clq, for example by binding of a fluorophor. The method therefore has the particular advantage that the protein can be subjected in its native state to the assay, thus I removing the risk of denaturation which would be present in the case of immobilizing and/or modifying said protein.
6 Another advantage of the method of the invention is the considerably reduced sample volume of the method of the invention compared to conventional methods. Thus it is possible to use volumes of less than 10 pl, thus minimizing material costs. Moreover, it is possible to use highly diluted solutions with CRP or Clq 5 concentrations of less than 1 nM, even less than 100 pM. It is, in addition, a very sensitive method. Furthermore, owing to the comments above, this is the first method which makes possible a high throughput screening for substances which influence complement activation due to binding of CRP to Cl1q. 0 In a preferred embodiment of the method of the invention, the signal is transferred from the at least one compound or group of compounds according to (a) (donor group) to the at least one compound or group of compounds according to (b) (acceptor group) via singlet oxygen. 5 In this case, the donor group preferably comprises a compound which can convert triplet oxygen to singlet oxygen after excitation by a laser, and the acceptor group comprises at least one first compound excitable by singlet oxygen and a second compound capable of absorbing in an emissionless manner and emitting in the form of fluorescence radiation the energy absorbed by the group excitable by singlet 0 oxygen. The singlet oxygen formed may diffuse from the donor group to the acceptor group and react with the chemiluminescent substances present there. The energy released in the process is transferred to the fluorophores which finally emit said energy in the 5 form of fluorescence radiation which can be detected using a photomultiplier. A precondition for a detectable signal is the spatial proximity of donor and acceptor beads, since singlet oxygen is unstable and decays in aqueous solution. Therefore, the binding components to be used in this method are chosen in such a way that, when the binding event occurs, the distance between the donor and acceptor groups D) is preferably less than 200 nm, since at a larger distance an effective energy transfer by means of singlet oxygen is not possible, due to the decay time of singlet oxygen.
7 Particular preference is given in this embodiment to donor group and acceptor group localized on particles, said particles preferably having an average diameter of between 150 and 250 nm, particularly preferably of approximately 200 nm. The preferred use of said particles here is such that the final concentration of donor 5 group-carrying particles is 1-40 pg/ml and the final concentration of acceptor group carrying particles is 1-80 pg/ml. The binding capacity of said particles may be, for example, from approximately 0.1 nM to 1 nM per pg/ml particles. Particular preference is given to using Alpha-Screen-Beads from Perkin-Elmer Life 0 Sciences as particles in the method. In this embodiment, the donor group is excited by irradiating at a wavelength of 680 nm, using a laser, and the radiation emitted by the acceptor group can be detected at a wavelength between 520 and 600 nm. Accordingly, it is possible, in this case, for the method to be carried out in such a way 5 that donor and acceptor beads carrying donor and acceptor groups are introduced initially. Components capable of binding either themselves or via further components to CRP or Clq are then bound to said donor and acceptor beads. As already mentioned above, these components may be either Clq or CRP or may be an anti CRP or anti-Clq antibody or else may be a secondary antibody directed against said D) anti-CRP or anti-Clq antibody. In a further preferred embodiment of the method of the invention, the signal is transferred from the at least one compound or group of compounds according to (b) (donor group) to the at least one compound or group of compounds according to (b) 5 (acceptor group) via emissionless energy transfer, particularly preferably via fluorescence resonance energy transfer. In this case it is possible to carry out the method, for example, in such a way that the at least one compound or group of compounds according to (a) (donor group) ) comprises a europium salt-containing compound and that the at least one compound or group of compounds according to (b) (acceptor group) may comprise allophycocyanine (Grepin et al. (2000), Drug Discovery Today 5, 212). Alternatively, 8 the donor and acceptor groups may be dyes suitable for emissionless energy transfer. It is furthermore possible to use all compounds known to the skilled worker which are suitable for emissionless energy transfer, in particular for fluorescence resonance energy transfer (see, for example, Pope et al. (1999), Drug Discovery 5 Today 4, 350). In this embodiment, preference is given to choosing the binding components to be used in such a way that the distance between the donor and acceptor groups after binding is less than 10 nm, since an effective emissionless energy transfer is not ) possible at a larger distance. In an embodiment preferred according to the invention, the method of the invention is used for determining the concentration of a CRP- or Clq-containing solution with unknown CRP or Clq content, said solution being preferably blood plasma or blood 5 serum or being blood plasma or blood serum diluted by means of a suitable physiological buffer or by means of water. Said method may be used, for example, for diagnostic purposes, in particular for determining the state of inflammation of an organism and/or for determining the risk of cardiac arrest and/or stroke. ) The present invention therefore likewise relates to an HTS-capable, diagnostic assay system for determining a binding event between CRP or Clq and a component binding to CRP or Clq, comprising the following components: (a) at least one donor component or group of components containing at least one donor component, said donor component being a component which comprises at 5 least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said donor component being capable of binding directly or via one or more components from said group of components to CRP or Clq, (b) at least one acceptor component or group of components containing at least one ) acceptor component, said acceptor component being a component which comprises at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of 9 compounds according to (b) and said acceptor component being capable of binding directly or via one or more components of said group of components to CRP or Clq. The HTS-capable assay system here preferably comprises the following additional 5 components: (c) blood serum or blood plasma, or blood diluted in physiological buffer or water, (d) a light source for exciting the at least one compound or group of compounds according to (a), (e) a detection system for detecting the emitted electromagnetic radiation according ) to (b). In another preferred embodiment of the method of the invention, at least one test substance is added prior to step (a) and/or prior to step (b) and/or prior to step (c) and/or prior to step (d), in order to observe, whether said test substance influences 5 the binding event. In this way, it is possible to determine substances which act on the interaction between CRP or Clq and a binder, in particular on the interaction between CRP and Clq, in a modulating, inhibiting or activating manner. This preferably involves screening a library of test substances in the HTS method in order to determine a substance having the desired properties. ) The present invention therefore likewise relates to an HTS-capable assay system for determining active substances which act on the interaction between CRP or Clq and a component binding to CRP or Clq in a modulating manner, comprising the following components: 5 (a) at least one donor component or group of components containing at least one donor component, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said donor component being capable of binding directly or via one or more components from said group of components to ) CRP or Clq, (b) at least one acceptor component or group of components containing at least one acceptor component, said acceptor component being a component which comprises 10 at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) and said acceptor component being capable of binding directly or via one or more components of said group of components to CRP or Cl1q, 5 (c) at least one test compound. Said HTS-capable assay system here comprises preferably the following additional components: (d) a light source for exciting the at least one compound or group of compounds 0 according to (a), (e) a detection system for detecting the emitted electromagnetic radiation according to (b), (f) a CRP- or Clq-containing solution. 5 The HTS-capable assay systems of the invention are used here preferably for carrying out the above-described methods of the invention. Particular embodiments of the parts and components of the assay systems therefore correspond to the abovementioned particular embodiments employed in the methods of the invention. 0 Diagram 1 is a diagrammatic representation of the method described in the exemplary embodiment. Here, the donor component used was an anti-Clq antibody, the donor group being located on particles bound to said anti-Clq antibody. In the present case, the donor component can bind via Clq to the CRP. The acceptor component in the present case is an anti-rabbit secondary antibody, the acceptor 5 group being located on particles bound to said anti-rabbit secondary antibody. In the present case, the acceptor component can bind via an anti-CRP antibody from rabbit to the CRP.
11 Diagram 1 Light (520 - 620 nm) Acceptor Goat anti-rabbit Light Rabbit anti-CRP (680 nm) CRP Biotin Cq Donor Streptavidin Goat anti-Clq 5 Exemplary embodiment: binding assay for determining binding of CRP to Clq The experiment was carried out using the Alphascreen Detection Kit from Packard Bioscience which comprises donor and acceptor beads, said donor beads comprising compounds which, after excitation at a defined wavelength, can convert triplet 0 oxygen to singlet oxygen, and said acceptor beads comprising compounds excitable by singlet oxygen, and also compounds capable of receiving in the form of an emissionless energy transfer and then emitting in the form of fluorescence radiation energy from the excited compounds. The compounds mentioned are embedded here in each case in a hydrogel matrix. The beads used had already been precoated by 5 the manufacturer, namely the donor beads with streptavidin and the acceptor beads with anti-rabbit antibody.
12 Table 1: Overview of the materials used Reagents/plates Molecular weight or Supplier, catalog concentration number Microplate, 384K, PS, white Greiner 784075 C-reactive protein, human, 1 mg/ml, 115 kd (5mer) Calbiochem 236608 recombinant from E. coli clq, human 1 mg/ml, 410 kd Calbiochem 204876 Anti-CRP, rabbit 3.57 mg/ml, 165 kd Calbiochem 235752 AlphaScreen IgG detection kit Packard BioScience (Protein A) 6760617 AlphaScreen Rabbit IgG Packard BioScience detection kit 6760607 Anti-clq, goat Polyclonal serum Calbiochem 234390 Anti-streptavidin Polyclonal serum Sigma S6390 EZ-Link Sulfo-NHS-LC- Pierce 21430 biotinylation kit Sodium chloride 58.44 g/mol Merck 101540 Calcium chloride (CaCI 2 x 2 H 2 0) 147.02 g/mol Merck 102382 Tris(hydroxymethyl)- 157.6 g/mol Merck 108219 aminomethanehydrochloride (Tris) Bovine serum albumin (BSA) Sigma P7888 Phosphoryl choline chloride 329.7 g/mol Sigma P0378 Phosphate-buffered saline (Mg 2 Gibco BRL and Ca2+-free) (PBS) 14200-067 Slide-A-Lyzer mini dialysis units, Pierce P.69570 10,000 MWCO Dimethyl sulfoxide (DMSO) Merck KGaA, 1.02931 13 Reagents/plates Molecular weight or Supplier, catalog concentration number Ethanol Riedel de Haen, 32250 Pluronic F-68 10 % strength solution Sigma, P5556 Hydrochloric acid 1 M Merck, 109057 Sodium hydroxide solution 1 M Merck, 109137 Milli-Q-H 2 0 Preparation of the reaction buffer The following reaction buffer was used in the Alpha-Screen-System: 20 mM Tris-HCI, S pH 7.2,150 mM NaCI, 5 mM CaCI 2 , 1 mM phosphoryl choline, 0.1 % BSA. A stock solution of Tris-NaCI buffer was prepared by dissolving 3.15 g of Tris-HCI and 8.77 g of NaCI in H 2 0, adjusting the pH to 7.2 by means of 1 M NaOH and then adding H 2 0 to 1 I. The buffer is stored at room temperature. The reaction buffer was prepared by adding 36.7 mg of CaCI 2 , 12.9 mg of phosphoryl choline and 50 mg of BSA to 50 ml ) of Tris-NaCI buffer. Biotinylation of the anti-Clq antibody In order to enable the anti-Cl q antibody to bind to the streptavidin-coated donor beads, the former needed to be biotinylated first. To this end, 100 pl of anti-Clq polyclonal serum were dialyzed twice against 200 ml of PBS at room temperature for 1 hour. After adding 20 pl of 1.5 mM sulfo-NHS solution (in Milli-Q water), the solution was left standing at room temperature for 30 minutes and then dialyzed again twice against PBS, in order to remove excess biotinylation reagent. ) Assay procedure The assay was carried out by initially introducing 2 pl of donor bead/anti-CRP solution and then adding 2 pl of Clq, 2 pl of CRP and 2 pl of acceptor bead/anti CRP. This resulted in the following final concentrations: CRP: 1 nM; Clq: 10 nM; anti-CRP: 7.3 nM; anti-Clq: 1:1500; donor beads: 20 pg/ml; acceptor beads: 14 40 pg/ml. In the negative control, reaction buffer replaced the CRP solution, the Clq solution or both of these solutions. After incubating at room temperature for 2 hours, the data were read out by means of an AlphaQuest reader. 5 Results The measured intensities of the emitted radiation at a CRP concentration of 1 nM and a Clq concentration of 10 nM were as follows (photomultiplier counts are listed): In the absence of CRP and absence of Clq: 952 D In the presence of CRP and absence of Clq: 1255 In the absence of CRP and presence of Clq: 1114 In the presence of CRP and presence of Cl1q: 80376 As can be seen, the negative controls do not provide a positive result, while a strong 5 signal is visible when the Clq- and CRP-containing solutions are combined.
Claims (36)
1. A method for determining a binding event of two components binding directly or via one or more components to CRP, which comprises the following steps: 5 (a) initially introducing a CRP-containing solution, (b) adding at least one donor component or a group of components containing at least one donor component to said CRP-containing solution, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said ) donor component being capable of binding directly or via one or more components from said group of components to CRP, (c) adding at least one acceptor component or a group of components containing at least one acceptor component to said CRP-containing solution, said acceptor component being a component which comprises at least one compound or group of 5 compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to CRP, (d) exciting the at least one compound or group of compounds according to (b) ) (donor group) by means of a light source, (e) detecting the electromagnetic radiation emitted by the at least one compound or group of compounds according to (c) (acceptor group) in order to detect said binding event. 5
2. A method for determining a binding event of two components binding directly or via one or more components to Clq, which comprises the following steps: (a) initially introducing a Clq-containing solution, (b) adding at least one donor component or a group of components containing at least one donor component to said Clq-containing solution, said donor component ) being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said 16 donor component being capable of binding directly or via one or more components from said group of components to Clq, (c) adding at least one acceptor component or a group of components containing at least one acceptor component to said Clq-containing solution, said acceptor 5 component being a component which comprises at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to Clq, 0 (d) exciting the at least one compound or group of compounds according to (b) (donor group) by means of a light source, (e) detecting the electromagnetic radiation emitted by the at least one compound or group of compounds according to (c) (acceptor group) in order to detect said binding event. 5
3. The method as claimed in claim 1 or 2, wherein the electromagnetic radiation is fluorescence radiation.
4. The method as claimed in claim 1 or 2, wherein the light source according to (d) is 0 a laser or a lamp.
5. The method as claimed in claim 1 or 2, wherein detection according to (e) is carried out with the aid of a photomultiplier. 5
6. The method as claimed in claim 1, wherein the components of the group of components according to (b) and/or (c) can bind to CRP or to one another, in spatial succession.
7. The method as claimed in claim 2, wherein the components of the group of 0 components according to (b) and/or (c) can bind to Clq or to one another, in spatial succession. 17
8. A method as claimed in any of claims 1 to 7, wherein the components are polypeptides or comprise a polypeptide.
9. The method as claimed in claim 8, wherein at least one of the components is an 5 antibody.
10. The method as claimed in claim 9, wherein the antibody is a monoclonal or polyclonal antibody. 0
11. The method as claimed in claim 1, wherein at least one of the components is a natural binding partner of the CRP.
12. The method as claimed in claim 11, wherein the natural binding partner of the CRP is Clq. 5
13. The method as claimed in claim 12, wherein the group of components according to claim 1(a) or claim 1(b) comprises Clq and an anti-Clq antibody.
14. The method as claimed in claim 2, wherein at least one of the components is a 0 natural binding partner of the Clq.
15. The method as claimed in claim 14, wherein the natural binding partner is CRP.
16. The method as claimed in claim 15, wherein the group of components according 5 to claim 2(a) or claim 2(b) comprises CRP and an anti-CRP antibody.
17. The method as claimed in claim 1 or 2, wherein the signal is transferred from the at least one compound or group of compounds according to (b) (donor group) to the at least one compound or group of compounds according to (c) (acceptor group) by ) means of emissionless energy transfer. 18
18. The method as claimed in claim 17, wherein the emissionless energy transfer is a fluorescence resonance energy transfer.
19. The method as claimed in claim 1 or 2, wherein the signal is transferred via 5 singlet oxygen.
20. The method as claimed in claim 19, wherein the at least one compound or group of compounds according to claim 1(b) or 2(b) (donor group) comprises a compound which is able to convert triplet oxygen to singlet oxygen after excitation by a laser and ) wherein the at least one compound or group of compounds according to claim 1(b) or 2(b) (acceptor group) comprise at least one first compound excitable by singlet oxygen and comprises at least one second compound capable of absorbing in an emissionless manner and emitting in the form of fluorescence radiation the energy absorbed by said compound excitable by singlet oxygen. 5
21. The method as claimed in claim 20, wherein the donor group and/or the acceptor group are localized on particles.
22. The method as claimed in claim 21, wherein the particles have an average ) diameter of approximately 200 nm.
23. The method as claimed in any of claims 1 to 22, which is used for determining the concentration of a CRP-containing solution with an unknown CRP content. 5
24. The method as claimed in any of claims 1 to 22, which is used for determining the concentration of a Clq-containing solution with an unknown Clq content.
25. The method as claimed in claim 23 or 24 wherein the solution is blood serum, blood plasma, or blood serum or blood plasma diluted by means of a physiological ) buffer or by means of water. 19
26. The method as claimed in claim 25, which is a diagnostic method for determining the state of inflammation of an organism and/or for determining the risk of cardiac arrest and/or stroke. 5
27. The method as claimed in any of the preceding claims, which is an HTS-capable homogeneous method which may be carried out as a one-step method.
28. The method as claimed in claim 1, comprising the additional step of adding at least one test substance prior to step (a) and/or prior to step (b) and/or prior to step 0 (c) and/or prior to step (d), in order to observe whether said test substance influences the binding event between CRP and CRP-binding component.
29. The method as claimed in claim 2, comprising the additional step of adding at least one test substance prior to step (a) and/or prior to step (b) and/or prior to step 5 (c) and/or prior to step (d), in order to observe whether said test substance influences the binding event between Clq and Clq-binding component.
30. The method as claimed in claim 28 or 29, which is used for determining substances which act on the binding event in a modulating, inhibiting or activating 0 manner.
31. An HTS-capable, diagnostic assay system for determining a binding event between CRP and a component binding to CRP, comprising the following components: 5 (a) at least one donor component or group of components containing at least one donor component, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said donor component being capable of binding directly or via one or more components from said group of components to ) CRP, (b) at least one acceptor component or group of components containing at least one acceptor component, said acceptor component being a component which comprises 20 at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of 5 components to CRP.
32. An HTS-capable, diagnostic assay system for determining a binding event between Clq and a component binding to Clq, comprising the following components: 0 (a) at least one donor component or group of components containing at least one donor component, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group) and said donor component being capable of binding directly or via one or more components from said group of components to 5 Clq, (b) at least one acceptor component or group of components containing at least one acceptor component, said acceptor component being a component which comprises at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of 0 compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to Clq.
33. The HTS-capable assay system as claimed in claim 31 or 32, comprising the 5 following additional components: (c) blood serum or blood plasma, or blood serum or blood plasma diluted in physiological buffer or by means of water, (d) a light source for exciting the at least one compound or group of compounds according to (a) (donor group), ) (e) a detection system for detecting the emitted electromagnetic radiation according to (b). 21
34. An HTS-capable assay system for determining active substances which act on the interaction between CRP and a component binding to CRP in a modulating manner, comprising the following components: (a) at least one donor component or group of components containing at least one 5 donor component, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group), and said donor component being capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (a), and said donor ) component being capable of binding directly or via one or more components from said group of components to CRP, (b) at least one acceptor component or group of components containing at least one acceptor component, said acceptor component being a component which comprises at least one compound or group of compounds capable of receiving and emitting in 5 the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to CRP, (c) at least one test compound.
35. An HTS-capable assay system for determining active substances which act on the interaction between Clq and a component binding to Clq in a modulating manner, comprising the following components: (a) at least one donor component or group of components containing at least one 5 donor component, said donor component being a component which comprises at least one compound or group of compounds capable of emitting a signal after excitation by a light source (donor group), and said donor component being capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of compounds according to (a), and said donor ) component being capable of binding directly or via one or more components from said group of components to Clq, 22 (b) at least one acceptor component or group of components containing at least one acceptor component, said acceptor component being a component which comprises at least one compound or group of compounds capable of receiving and emitting in the form of electromagnetic radiation the signal emitted by the compound or group of 5 compounds according to (b) (acceptor group) and said acceptor component being capable of binding directly or via one or more components of said group of components to Clq, (c) at least one test compound. 0
36. The HTS-capable assay system as claimed in claim 34 or 35, comprising the following additional components: (d) a light source for exciting the at least one compound or group of compounds according to (a) (donor group), (e) a detection system for detecting the emitted electromagnetic radiation according 5 to (b).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10226011A DE10226011A1 (en) | 2002-06-12 | 2002-06-12 | HTS-capable method and test system for determining the interaction between c-reactive protein and components that bind to C-reactive protein |
| DE10226011.7 | 2002-06-12 | ||
| PCT/EP2003/006038 WO2003107000A2 (en) | 2002-06-12 | 2003-06-10 | Hts-capable method and testing system for determining the interaction between a c-reactive protein and constituents that bind to a c-reactive protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2003250344A1 true AU2003250344A1 (en) | 2003-12-31 |
Family
ID=29718976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003250344A Abandoned AU2003250344A1 (en) | 2002-06-12 | 2003-06-10 | Determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1516187A2 (en) |
| JP (1) | JP2005529348A (en) |
| CN (1) | CN1745300A (en) |
| AR (1) | AR040259A1 (en) |
| AU (1) | AU2003250344A1 (en) |
| BR (1) | BR0311709A (en) |
| CA (1) | CA2489021A1 (en) |
| DE (1) | DE10226011A1 (en) |
| MX (1) | MXPA04012232A (en) |
| NO (1) | NO20050037L (en) |
| RU (1) | RU2005100042A (en) |
| TW (1) | TW200411179A (en) |
| WO (1) | WO2003107000A2 (en) |
| ZA (1) | ZA200409199B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102721813A (en) * | 2012-07-09 | 2012-10-10 | 沃克(天津)生物科技有限公司 | Homogeneous luminous immunoassay assay kit for prostate specific antigen and detection method therefor |
| CN103852465A (en) * | 2012-11-30 | 2014-06-11 | 通用电气公司 | Method and apparatus for detecting marker protein |
| JP2018533017A (en) * | 2015-10-02 | 2018-11-08 | ティージーアール バイオサイエンシス ピーティーワイ エルティーディー． | Specimen detection with multiple substrates |
| CN111398580B (en) * | 2017-11-03 | 2023-06-13 | 科美诊断技术股份有限公司 | Method for detecting target IgM antibody in sample |
| CN109752332A (en) * | 2017-11-07 | 2019-05-14 | 重庆中元汇吉生物技术有限公司 | A kind of C1Q detection kit |
| CN108490194A (en) * | 2018-02-11 | 2018-09-04 | 北京科美生物技术有限公司 | Detect the homogeneous immunological detection reagent suit and its preparation method and application of follicular stimulating hormone |
| CN108445238A (en) * | 2018-02-11 | 2018-08-24 | 北京科美生物技术有限公司 | Detect the homogeneous immunological detection reagent suit and its preparation method and application of interstitialcellstimulating hormone (ICSH) |
| CN108445216B (en) * | 2018-02-11 | 2021-10-15 | 科美诊断技术股份有限公司 | Human anti-mullerian hormone determination kit and preparation method and application thereof |
| CN108169497A (en) * | 2018-02-11 | 2018-06-15 | 北京科美生物技术有限公司 | Human prolactin detection kit and preparation method and application |
| CN108445239B (en) * | 2018-02-11 | 2021-11-02 | 科美诊断技术股份有限公司 | Homogeneous phase immunoassay reagent kit for detecting beta human chorionic gonadotropin, and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU633488B2 (en) * | 1988-04-04 | 1993-02-04 | Northwestern University | Binding of immune complexes by modified forms of c-reactive protein |
| US6140490A (en) * | 1996-02-01 | 2000-10-31 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US5283238A (en) * | 1992-04-24 | 1994-02-01 | Immtech International, Inc. | Methods of treating cancer using modified C-reactive protein |
| CA2170873A1 (en) * | 1993-09-03 | 1995-03-09 | Dariush Davalian | Fluorescent oxygen channeling immunoassays |
| US6303325B1 (en) * | 1998-05-29 | 2001-10-16 | Dade Behring Inc. | Method for detecting analytes |
-
2002
- 2002-06-12 DE DE10226011A patent/DE10226011A1/en not_active Withdrawn
-
2003
- 2003-06-10 MX MXPA04012232A patent/MXPA04012232A/en not_active Application Discontinuation
- 2003-06-10 WO PCT/EP2003/006038 patent/WO2003107000A2/en not_active Application Discontinuation
- 2003-06-10 TW TW092115617A patent/TW200411179A/en unknown
- 2003-06-10 RU RU2005100042/15A patent/RU2005100042A/en not_active Application Discontinuation
- 2003-06-10 CA CA002489021A patent/CA2489021A1/en not_active Abandoned
- 2003-06-10 JP JP2004513768A patent/JP2005529348A/en active Pending
- 2003-06-10 CN CNA03813442XA patent/CN1745300A/en active Pending
- 2003-06-10 BR BR0311709-0A patent/BR0311709A/en not_active IP Right Cessation
- 2003-06-10 EP EP03759923A patent/EP1516187A2/en not_active Withdrawn
- 2003-06-10 AU AU2003250344A patent/AU2003250344A1/en not_active Abandoned
- 2003-06-10 AR ARP030102067A patent/AR040259A1/en unknown
-
2004
- 2004-11-17 ZA ZA200409199A patent/ZA200409199B/en unknown
-
2005
- 2005-01-04 NO NO20050037A patent/NO20050037L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR040259A1 (en) | 2005-03-23 |
| BR0311709A (en) | 2005-03-15 |
| CN1745300A (en) | 2006-03-08 |
| WO2003107000A3 (en) | 2004-05-27 |
| MXPA04012232A (en) | 2005-02-25 |
| TW200411179A (en) | 2004-07-01 |
| DE10226011A1 (en) | 2004-01-08 |
| ZA200409199B (en) | 2005-05-18 |
| CA2489021A1 (en) | 2003-12-24 |
| JP2005529348A (en) | 2005-09-29 |
| EP1516187A2 (en) | 2005-03-23 |
| WO2003107000A2 (en) | 2003-12-24 |
| RU2005100042A (en) | 2006-07-20 |
| NO20050037L (en) | 2005-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20030087311A1 (en) | Method of identifying energy transfer sensors for analytes | |
| JPS62239057A (en) | Fluorescent polarizing immunity testing method and reagent used for said testing method | |
| Gu et al. | Regulation of dynamin oligomerization in cells: the role of dynamin–actin interactions and its GTPase activity | |
| AU2003250344A1 (en) | Determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein | |
| US5550030A (en) | Reagent for endotoxin-specific assay | |
| JP2007502417A (en) | Detection and characterization of molecular complexes | |
| US20030232394A1 (en) | High throughput screening method and assay system for determining the interaction between C-reactive protein and components binding to it | |
| JP4242499B2 (en) | Method for measuring CRP using phosphorylcholine | |
| KR20050020985A (en) | Determining the interaction between a C-reactive protein and constituents that bind to a C-reactive protein | |
| ES2268747T3 (en) | DETERMINATION OF DETERMINATION OF FACTORS ASSOCIATED WITH SOLID PHASES. | |
| FI100276B (en) | Method for non-competitive determination of analytes | |
| CN112198310B (en) | C-reactive protein and serum amyloid A combined detection test strip, kit and preparation method of test strip | |
| EP3430402A1 (en) | Detection method and means therefor | |
| JP4437003B2 (en) | Method for screening compound that modulates interaction between EVH1 domain or protein having EVH1 domain and protein having EVH1 binding domain or EVH1 binding domain, and method for detecting the interaction | |
| WO1988005538A1 (en) | Method of detecting and quantifying ligands in liquids | |
| EP0556745A1 (en) | Method for detection of anti-wheat-protein antibodies | |
| JP3742415B2 (en) | Reagent for immunoassay for detecting autoantibody against RB1 gene product | |
| US11802881B2 (en) | Saturation binding ratiometric assay | |
| US20040241766A1 (en) | Carbamazepine assay | |
| AU1633501A (en) | Ex-vivo test kit for testing the effectiveness of reversers of multidrug resistance | |
| EP0601131A1 (en) | Binding of milk allergens to a solid phase | |
| JP2000111553A (en) | Measuring method for normal aggrecan and its application | |
| RU2538707C1 (en) | Method for determining level of toxicants in water, food products or physiological liquids, and test system | |
| Ito et al. | Combination of high anti‐SKI and low anti‐TMED5 antibody levels is preferable prognostic factor in esophageal carcinoma | |
| RU2547577C1 (en) | Method of determining level of toxicants in water, food products or body fluids and test system |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |